Company Overview

SureNano Science Ltd. is a Canadian nanotechnology and biotechnology company focused on the development and commercialization of proprietary delivery systems designed to improve the bioavailability, stability, and absorption of active ingredients. The company operates primarily in the health sciences, wellness, nutraceutical, and emerging cannabinoid delivery markets, with a business model centered on licensing, product development, and formulation technologies. Public disclosures indicate that the company’s core value proposition is its nano-emulsion and liposomal delivery platform, which is intended to enhance ingredient dispersion and efficacy in consumable products.

The company has positioned itself within the broader functional ingredient and advanced delivery technology sector by targeting manufacturers and brands seeking differentiated formulations for wellness and consumer health products. Revenue generation has historically been tied to technology licensing, white-label manufacturing relationships, formulation partnerships, and commercialization agreements. SureNano Science evolved from an early-stage research and development enterprise into a publicly traded commercialization-focused company listed in Canada, emphasizing intellectual property development and strategic partnerships in the nutraceutical and cannabinoid sectors. Certain historical operating details and financial scale metrics remain limited in publicly available disclosures.

Business Operations

SureNano Science’s operations are centered around its proprietary nano-delivery and emulsion technologies, which are intended to improve the effectiveness and absorption of ingredients used in ingestible and wellness-focused products. The company’s principal operating activities include research and development, formulation engineering, commercialization partnerships, and licensing arrangements. Public filings and investor materials indicate that the company has pursued applications in cannabinoids, vitamins, supplements, and other bioactive compounds where enhanced solubility and stability are commercially valuable.

Operationally, the company has primarily focused on North American markets, particularly Canada, while exploring broader commercialization opportunities through manufacturing and distribution relationships. SureNano Science has highlighted intellectual property development and formulation expertise as strategic assets. Publicly available information references collaborative relationships and commercial agreements with external product manufacturers and wellness-sector participants, though detailed disclosures regarding large-scale joint ventures or globally significant subsidiaries remain limited. Data inconclusive based on available public sources regarding the scale of international revenue contribution and long-term contractual partnerships.

Strategic Position & Investments

SureNano Science’s strategic direction has focused on expanding the commercial use of its delivery technologies across nutraceutical, wellness, and cannabinoid applications. The company has emphasized scaling commercialization through licensing arrangements, product partnerships, and intellectual property protection rather than building a large vertically integrated manufacturing footprint. This strategy aligns with broader industry trends favoring advanced bioavailability technologies in functional consumer products.

The company has also sought exposure to emerging sectors involving cannabinoid formulations and next-generation wellness products that require stable emulsification and enhanced ingredient absorption. Public disclosures indicate ongoing investment in formulation innovation and research capabilities. However, publicly verifiable information regarding major acquisitions, material portfolio investments, or large wholly owned operating subsidiaries remains limited. Data inconclusive based on available public sources concerning the long-term financial impact of announced commercialization initiatives and the extent of proprietary patent protections across jurisdictions.

Geographic Footprint

SureNano Science Ltd. is headquartered in Canada and has primarily operated within the Canadian market while pursuing broader commercialization opportunities in North America. The company’s business model appears structured around technology licensing and formulation partnerships that may support cross-border distribution opportunities, particularly in wellness and cannabinoid-related sectors where regulatory environments vary by jurisdiction.

Public materials suggest the company has explored international commercial potential through manufacturing and brand relationships rather than extensive direct foreign operations. Its market focus has generally emphasized regions with established nutraceutical and cannabis-adjacent consumer industries. However, detailed disclosures regarding physical international offices, material overseas subsidiaries, or region-specific revenue segmentation are limited in available public filings.

Leadership & Governance

SureNano Science Ltd. has operated under a management structure focused on technology commercialization, product innovation, and public market growth initiatives. Leadership communications in public filings and investor materials have emphasized intellectual property development, commercialization partnerships, and expansion within advanced wellness delivery systems. Governance oversight appears aligned with Canadian public company reporting standards applicable to listed issuers.

Key executives and leadership figures publicly associated with the company include:

• Mark Scott – Chief Executive Officer
• Ryan Construction – Chief Financial Officer

Additional executive and board-level information has appeared inconsistently across public disclosures and corporate updates. Data inconclusive based on available public sources regarding the full current executive leadership roster and any recent governance changes.